Photo from wikipedia
On 10 December 2020 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a conditional marketing authorisation for selpercatinib (Retevmo) for the… Click to show full abstract
On 10 December 2020 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a conditional marketing authorisation for selpercatinib (Retevmo) for the treatment of cancers that display a rearranged during transfection (RET) gene alterations: RET fusion-positive nonsmall-cell lung cancer (NSCLC), RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer (MTC).
Keywords:
rethinking treatment;
ret;
treatment ret;
thyroid;
lung
Journal Title: ESMO Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ESMO Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!